1. Dual therapy (ritonavir boosted atazanavir + raltegravir) versus standard triple therapy (ritonavir boosted atazanavir + tenofovir/emtricitabine) in patients failing first line therapy: 48 week results from a randomized pilot study. (August 2018) Authors: Sued, O.; Figueroa, M.I.; Cesar, C.; Patterson, P.; Yamamoto, C.; fink, V.; luna, N.; Gun, A.; Cahn, P. Journal: International journal of infectious diseases Issue: Volume 73(2018)Supplement Page Start: 23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Functionality of CD8+ T-cells in subjects under cART: implications on cure strategies. (August 2018) Authors: Salido, J.; Ruiz, M.J.; Trifone, C.; Figueroa, M.I.; Caruso, M.P.; Gherardi, M.M.; Sued, O.; Horacio, S.; Natalia, L.; Ghiglione, Y.; turk, G. Journal: International journal of infectious diseases Issue: Volume 73(2018)Supplement Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗